| Co-Investigator(Kenkyū-buntansha) |
衛藤 剛 大分大学, 医学部, 講師 (00404369)
平塚 孝宏 大分大学, 医学部, 助教 (20600886)
猪股 雅史 大分大学, 医学部, 教授 (60315330)
赤木 智徳 大分大学, 医学部, 助教 (80572007)
北野 正剛 大分大学, 法人本部, 学長 (90169871)
|
|---|
| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2017: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2015: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
|
|---|
| Outline of Final Research Achievements |
We performed DNA microarray using mRNA collected from biopsy specimens in esophageal cancer. Gene expression of correlation with lymphatic invasion and lymph node metastasis is now being analyzed. Additionally, the predictor of pathological complete response(pCR) was investigated in the cases treated with neoadjuvant chemotherapy involved Docetaxel/Cisplatin/5-fulorouracil (NAC-DCF). Consequently, seventeen molecules including transcription factor E2F, T-cell-specific transcription factor, Src (known as“proto-oncogene tyrosine-protein kinase of sarcoma”), interferon regulatory factor 1, thymidylate synthase, cyclin B, cyclin-dependent kinase(CDK) 4, CDK, caspase-1, vitamin D receptor, histone deacetylase, MAPK/ERK kinase, bcl-2-associated X protein, runt-related transcription factor 1, PR domain zinc finger protein 1, platelet-derived growth factor receptor, and interleukin 1, were identified as candidate molecules. These were published in a journal with peer review (PLoS One 2017).
|
